Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rAAV1.CMV.huFollistatin344 in Duchenne Muscular Dystrophy
NCT02354781Phase 2Completed
- Start
- Jan 2015
- Primary completion
- Nov 2017
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rAAV1.CMV.huFollistatin344 in Duchenne muscular dystrophy (DMD). Primary endpoint: Dose Limiting Toxicity Adverse Events at 2 years. Started Jan 2015; status: completed.
02
Drugs
rAAV1.CMV.huFollistatin344
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02354781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354781.